Logo-jpd
J Parathyr Dis. 2018;6(1): 26-28. doi: 10.15171/jpd.2018.09

Epidemiology and Prevention

Persistent hyperparathyroidism after kidney transplantation; updates on the risk factors and its complications

Charat Thongprayoon 1, Wisit Cheungpasitporn 2 *

Cited by CrossRef: 4

1- Balcázar-Hernández L, Vargas-Ortega G, González-Virla B, Cruz-López M, Rodríguez-Gómez R, Espinoza-Pérez R, Cuevas-García C, Mendoza-Zubieta V. Biochemical Characteristics of Bone Mineral Metabolism before and throughout the First Year after Kidney Transplantation, Persistent Hyperparathyroidism, and Risk Factors in a Latin Population. International Journal of Endocrinology. 2020;2020:1 [Crossref]
2- Uçar Z, Sinangil A, Koç Y, Barlas İ, Ecder S, Akin E. The Effect of Alendronate on Bone Mineral Disorder in Renal Transplant Patients. Transplantation Proceedings. 2022;54(3):658 [Crossref]
3- Hasparyk U, Vigil F, Bartolomei V, Nunes V, Simões e Silva A. Chronic Kidney Disease-Mineral Bone Disease Biomarkers in Kidney Transplant Patients. CMC. 2022;29(31):5230 [Crossref]
4- Thongprayoon C, Hansrivijit P, Leeaphorn N, Acharya P, Torres-Ortiz A, Kaewput W, Kovvuru K, Kanduri S, Bathini T, Cheungpasitporn W. Recent Advances and Clinical Outcomes of Kidney Transplantation. JCM. 2020;9(4):1193 [Crossref]